---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018314"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:20:08.608801+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B

## Summary
- $115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.
- CVR pays $5 if cumulative worldwide sales of anito-cel exceed $6B by Dec 31, 2029.
- FDA accepted BLA for anito-cel in relapsed/refractory multiple myeloma; PDUFA date Dec 23, 2026.
- Transaction expected to close Q2 2026; requires majority tender, regulatory approvals, and customary conditions.
- Gilead currently owns ~11.5% of Arcellx; deal builds on existing Kite collaboration.

## SEC filing metadata
- accession: 0001104659-26-018314
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/0001104659-26-018314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018314
- JSON: https://secwatch.observer/filing/0001104659-26-018314.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018314.txt

## Key facts
- Material Agreements
  GILEAD SCIENCES, INC. entered into Merger Agreement with Arcellx, Inc. (effective 2026-02-22).
  - Action: entry
  - Agreement: merger
  - Counterparty: Arcellx, Inc.
  - Effective: 2026-02-22
  source text: On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, Arcellx, Inc., a Delaware corporation (the “ Company ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/0001104659-26-018314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.